Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)
Manage episode 297177464 series 2907690
Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company's ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer's disease, Lewy Body Dementia and Parkinson's. In short, Bioasis' final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!